(Q38148969)

29 August 2017

title

Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer (English)

1 reference

29 August 2017

1 reference

B Solomon

1

1 reference

29 August 2017

K D Wilner

series ordinal

2

1 reference

29 August 2017

A T Shaw

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

3 October 2013

1 reference

Clinical Pharmacology & Therapeutics

29 August 2017

published in

1 reference

29 August 2017

volume

95

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

15-23

1 reference

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

The anaplastic lymphoma kinase in the pathogenesis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Jeb signals through the Alk receptor tyrosine kinase to drive visceral muscle fusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Jelly belly protein activates the receptor tyrosine kinase Alk to specify visceral muscle pioneers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

C. elegans anaplastic lymphoma kinase ortholog SCD-2 controls dauer formation by modulating TGF-beta signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Renal cell carcinoma with novel VCL-ALK fusion: new representative of ALK-associated tumor spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Oncogene addiction: setting the stage for molecularly targeted cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Comprehensive histologic analysis of ALK-rearranged lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT- PCR on paraffin-embedded tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Fluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Discovery of ALK-PTPN3 gene fusion from human non-small cell lung carcinoma cell line using next generation RNA sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

ROS1 rearrangements define a unique molecular class of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Heart rate decrease during crizotinib treatment and potential correlation to clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

ALK in lung cancer: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

Crizotinib and testing for ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.200

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2013.200

1 reference

29 August 2017

1 reference